Characterization of immune responses caused by bovine leukemia virus envelope peptides in sheep.

To study the immunomodulative activity caused by bovine leukemia virus envelope (BLV Env) peptide, sheep were immunized with two kinds of Th-epitope peptides, peptide 98 (BLV Env 98-117), and 61 (BLV Env 61-78). Four of eight immunized sheep showed specific proliferative responses against both of the peptide stimulations. To characterize the cells responding to the peptides, peptide-specific cells were established from the responding sheep by the continuous stimulation of peripheral blood mononuclear cells (PBMCs) with either peptide 98 or 61 in vitro. The peptide 98-specific cells consisted of CD4-positive cells, whereas the peptide 61-specific cells consisted of CD8-positive cells and MHC class II-positive cells. In addition, cytokine profile analysis indicated that the peptide 98-stimulated cells expressed IFN-gamma but not IL-10, although the peptide 61-stimulated cells expressed IL-10 but not IFN-gamma. These results show that BLV envelope peptides 98 and 61 can modulate immune responses of sheep lymphocytes in different ways and may contribute to the pathogenesis of BLV infection.

[1]  G. Splitter,et al.  Interleukin-12 p40 mRNA Expression in Bovine Leukemia Virus-Infected Animals: Increase in Alymphocytosis but Decrease in Persistent Lymphocytosis , 1998, Journal of Virology.

[2]  W. Davis,et al.  B-Lymphocyte Proliferation during Bovine Leukemia VirusInduced Persistent Lymphocytosis Is Enhanced by T-Lymphocyte-Derived Interleukin-2 , 1998, Journal of Virology.

[3]  P. V. van Rijn,et al.  Glycoprotein Erns of pestiviruses induces apoptosis in lymphocytes of several species , 1997, Journal of virology.

[4]  G. Splitter,et al.  Increased interleukin-10 mRNA expression in tumor-bearing or persistently lymphocytotic animals infected with bovine leukemia virus , 1996, Journal of virology.

[5]  M. Onuma,et al.  Induction of bovine leukaemia virus Env-specific Th-1 type immunity in mice by vaccination with short synthesized peptide-liposome. , 1996, Vaccine.

[6]  K. Ohashi,et al.  An effective peptide vaccine to eliminate bovine leukaemia virus (BLV) infected cells in carrier sheep. , 1996, Vaccine.

[7]  R. Kettmann,et al.  Cellular pathways involved in the ex vivo expression of bovine leukemia virus , 1996, Journal of virology.

[8]  N. Day,et al.  Immunosuppressive retroviral peptides: cAMP and cytokine patterns. , 1995, Immunology today.

[9]  W. Davis,et al.  Up-regulation of IL-2 receptor alpha and MHC class II expression on lymphocyte subpopulations from bovine leukemia virus infected lymphocytotic cows. , 1995, Veterinary immunology and immunopathology.

[10]  N. Day,et al.  Induction of intracellular cAMP by a synthetic retroviral envelope peptide: a possible mechanism of immunopathogenesis in retroviral infections. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[11]  N. Day,et al.  Differential modulation of Th1- and Th2-related cytokine mRNA expression by a synthetic peptide homologous to a conserved domain within retroviral envelope protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  F. Annunziato,et al.  Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection , 1994, The Journal of experimental medicine.

[13]  A. Burny,et al.  Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51 , 1993, Journal of virology.

[14]  M. Gatei,et al.  T-cell responses to highly conserved CD4 and CD8 epitopes on the outer membrane protein of bovine leukemia virus: relevance to vaccine development , 1993, Journal of virology.

[15]  X. Jin,et al.  Quantitative analysis of the human immunodeficiency virus type 1 (HIV- 1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein- Barr virus in late disease , 1993, The Journal of experimental medicine.

[16]  M. Clerici,et al.  A TH1-->TH2 switch is a critical step in the etiology of HIV infection. , 1993, Immunology today.

[17]  W. A. Jensen,et al.  Inhibition of protein kinase C results in decreased expression of bovine leukemia virus , 1992, Journal of virology.

[18]  J. Convit,et al.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. , 1991, Science.

[19]  J. Rovnak,et al.  In vivo transcription of the bovine leukemia virus tax/rex region in normal and neoplastic lymphocytes of cattle and sheep , 1991, Journal of virology.

[20]  R. Gottlieb,et al.  Inhibition of protein kinase C by a peptide conjugate homologous to a domain of the retroviral protein p15E. , 1990, Journal of immunology.

[21]  L. Babiuk,et al.  Inhibition of antigen-induced and interleukin-2-induced proliferation of bovine peripheral blood leukocytes by inactivated bovine herpes virus 1 , 1990, Journal of virology.

[22]  T. Mosmann,et al.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. , 1990, Science.

[23]  I. Chen,et al.  Regulation of human T cell leukemia virus expression 1 , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. , 1990, Disease markers.

[25]  M. Dodon,et al.  Direct activation of resting T lymphocytes by human T-lymphotropic virus type I , 1987, Nature.

[26]  R. Gallo,et al.  Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Esteban,et al.  Characterization of the blood lymphocyte population in cattle infected with the bovine leukemia virus. , 1985, Cancer research.

[28]  A. Burny,et al.  Bovine leukemia virus: an exogenous RNA oncogenic virus. , 1976, Proceedings of the National Academy of Sciences of the United States of America.